Lantheus Holdings, Inc. Interest Expense Nonoperating
Lantheus Holdings, Inc. (LNTH) reported Interest Expense Nonoperating of $4.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Lantheus Holdings, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $4.92M, a 0.04% decline year-over-year.
- Lantheus Holdings, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $4.86M, a 1.25% increase year-over-year.
- Lantheus Holdings, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $5.08M, a 0.65% increase year-over-year.
- Lantheus Holdings, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $4.95M, a 0.96% increase year-over-year.
- Lantheus Holdings, Inc. interest expense nonoperating for fiscal 2025 was $19.75M, a 0.41% increase from fiscal 2024.
- Lantheus Holdings, Inc. interest expense nonoperating for fiscal 2024 was $19.67M, a 1.75% decline from fiscal 2023.
- Lantheus Holdings, Inc. interest expense nonoperating for fiscal 2023 was $20.02M, a 178.62% increase from fiscal 2022.
- Lantheus Holdings, Inc. interest expense nonoperating for fiscal 2022 was $7.18M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.92M 10-Q · filed 2026-08-06 | $9.78M 10-Q · filed 2026-08-06 | $14.86M derived: sum of 3 quarters · filed 2026-08-06 | $19.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.86M 10-Q · filed 2026-05-07 | $9.94M derived: sum of 2 quarters · filed 2026-05-07 | $14.89M derived: sum of 3 quarters · filed 2026-05-07 | $19.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.03M derived: sum of 2 quarters · filed 2026-02-26 | $14.95M derived: sum of 3 quarters · filed 2026-08-06 | $19.75M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.95M 10-Q · filed 2025-11-06 | $9.87M derived: sum of 2 quarters · filed 2026-08-06 | $14.67M 10-Q · filed 2025-11-06 | $19.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.92M 10-Q · filed 2026-08-06 | $9.72M 10-Q · filed 2026-08-06 | $14.77M derived: sum of 3 quarters · filed 2026-08-06 | $19.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.80M 10-Q · filed 2026-05-07 | $9.85M derived: sum of 2 quarters · filed 2026-05-07 | $14.75M derived: sum of 3 quarters · filed 2026-05-07 | $19.61M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.95M derived: sum of 2 quarters · filed 2026-02-26 | $14.81M derived: sum of 3 quarters · filed 2026-02-26 | $19.67M 10-K · filed 2026-02-26 |
| 2024-09-30 | $4.90M 10-Q · filed 2025-11-06 | $9.77M derived: sum of 2 quarters · filed 2025-11-06 | $14.62M 10-Q · filed 2025-11-06 | $19.66M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.86M 10-Q · filed 2025-08-06 | $9.72M 10-Q · filed 2025-08-06 | $14.76M derived: sum of 3 quarters · filed 2026-02-26 | $19.82M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $4.86M 10-Q · filed 2025-05-07 | $9.90M derived: sum of 2 quarters · filed 2026-02-26 | $14.95M derived: sum of 3 quarters · filed 2026-02-26 | $19.89M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.10M derived: sum of 2 quarters · filed 2026-02-26 | $15.03M derived: sum of 3 quarters · filed 2026-02-26 | $20.02M 10-K · filed 2026-02-26 |
| 2023-09-30 | $5.05M 10-Q · filed 2024-11-06 | $9.99M derived: sum of 2 quarters · filed 2024-11-06 | $14.98M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $4.93M 10-Q · filed 2024-07-31 | $9.92M 10-Q · filed 2024-07-31 | ||
| 2022-12-31 | $7.18M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |